US: J&J says FTC probing efforts to protect arthritis drug Remicade

US: J&J says FTC probing efforts to protect arthritis drug Remicade

The Federal Trade Commission (FTC) issued civil subpoenas to Johnson & Johnson (J&J) in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company stated in a regulatory filing on Monday, July 29. J&J stated that the FTC had issued a “civil investigative […]

US: J&J can’t arbitrate Remicade antitrust case argues Rochester

US: J&J can’t arbitrate Remicade antitrust case argues Rochester

A drug wholesaler is urging a federal appeals court to not send a lawsuit accusing Johnson & Johnson (J&J) of seeking to suppress competition for its blockbuster rheumatoid arthritis drug Remicade to arbitration. Remicade has been on the market since receiving FDA approval in 1998. From 1998 to 2016, J&J had what the suit calls […]

Canada: Competition Bureau completes investigation of Janssen

Canada: Competition Bureau completes investigation of Janssen

The Competition Bureau announced Wednesday, February 20, that it closed an investigation into allegations of abuse of dominance by Janssen, a Canadian pharmaceutical company owned by Johnson & Johnson. The Bureau’s investigation considered whether Janssen was engaging in conduct that shielded its biologic drug, Remicade, from competition from biosimilar drugs, like Inflectra and Renflexis. This […]

US: Johnson & Johnson to buy Auris Health for $3.4B

US: Johnson & Johnson to buy Auris Health for $3.4B

On Wednesday, February 13, Johnson & Johnson (J&J) announced it would buy robotic surgery firm Auris Health for US$3.4 billion in cash. The purchase gives J&J, one of the world’s largest maker of health products, an entry into robotics and builds on the company’s partnership with Alphabet’s Verily. “In this new era of health care, […]

US: Judge rules J&J must face antitrust suits

US: Judge rules J&J must face antitrust suits

US District Judge Curtis Joyner has rejected Johnson & Johnson’s (J&J) bid to dismiss class action lawsuits by retailers and insurers claiming the drugmaker conducted an anticompetitive scheme to shield its blockbuster rheumatoid arthritis drug Remicade from competition. The judge ruled the lawsuits sufficiently alleged J&J entered into contracts with insurers that required them to […]

US: Walgreens and Kroger file antitrust suit against Johnson & Johnson

US: Walgreens and Kroger file antitrust suit against Johnson & Johnson

Last week, Walgreens and Kroger filed an antitrust lawsuit against J&J and it subsidiary, Janssen, in the US District Court for the Eastern District of Pennsylvania—the same court that Pfizer also brought suit against J&J in 2017—making similar allegations to the earlier suit. Walgreens and Kroger are seeking a permanent injunctive and damages “arising out […]

EU: Johson and Johnson get approval for $30bn Actelion deal

EU: Johson and Johnson get approval for $30bn Actelion deal

Johnson & Johnson said the approval of its proposed acquisition of Swiss biotech firm Actelion by the European Commission on Friday meant all regulatory approvals required to complete the $30 billion deal had now been received. The US company said it expected settlement of the all-cash public tender offer by its Swiss subsidiary, Janssen Holding, […]

EU: Johnson & Johnson offers concessions over Actelion deal

EU: Johnson & Johnson offers concessions over Actelion deal

US healthcare giant Johnson & Johnson has offered concessions in a bid to address EU antitrust concerns over its $30 billion bid for Swiss biotech company Actelion (ATLN.S), the European Commission said on Thursday. The EU competition enforcer extended its review of the deal to June 12 from May 24, according to a filing on […]

Rethinking Resale Pricing in China

Ninette Dodoo, Oct 31, 2013 CPI Asia Column edited by Vanessa Yanhua Zhang (Global Economics Group) presents: Rethinking Resale Pricing in China – Ninette Dodoo* (Clifford Chance) Click here for a pdf version of this article. Introduction In the past year, resale price maintenance (RPM) agreements have attracted attention in China’s courts as well as […]

The Use of Economic Analysis in RPM Cases in China: Is There Gold at the End of the Rainbow?

Yan Yu, Oct 28, 2013 This paper revisits the economics of resale price maintenance, comments on the extent to which economic principles were embraced by the Shanghai High People’s Court in ruling the first RPM private litigation in China involving Johnson & Johnson and Rainbow, and discusses potential implications for the use of economic analysis […]